CMAJ • March 27, 2007; 176 (7). First published March 20, 2007; doi:10.1503/cmaj.070269
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow Correction (v177,p66)
Right arrow Correction (v176,p1310)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Comeau, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Comeau, P.
Related Collections
Right arrow Drugs: immunological products and vaccines
Right arrow Cervical screening

Debate begins over public funding for HPV vaccine

Pauline Comeau

Ottawa


Figure 5
View larger version (134K):
[in this window]
[in a new window]

  		Figure. The National Advisory Committee on Immunization is recommending that females aged 9–26 receive the new HPV vaccine. The question is, who will pay? Photo by: Canapress